RE:RE:Aphria's second quarter results were only 6 weeks sales....INVSTIGAT0R wrote: Med sales before were 13 mil. 19 mil for 6 weeks rec sales so that would have been about 19-13 = 6 million in 6 weeks for rec alone. Let's extrapolate and say 12 weeks = 12 million of rec. Add that to our med sales and we should see a bare minimum of 25 million in quarter 3 not including CC Pharma. CC Pharma should add another 30 million minimum so we're looking at about 55 million next quarter as an easy target to make, the same as Aurora yet they're at 10 billion while we're at 3. We'll also see a drop in EPS quarter over quarter as the one time investments from the sale of LHS and Hiku shares won't be there obviously. Also note that I have only been ordering Aphria products (for the most part) and have observed packaging dates of September 9th, 2018 being delivered in January 2019, which means that we are currently still trying to sell inventory due to supply chain issues when we SHOULD have burned through ALL inventory in the first few weeks of sales had their been enough places to sell our products.
So Q3 = 55 million minimum (25+ from weed sales and 30+ from CC Pharma), less cash on hand and a drop in EPS. We'll need a big catalyst like a global partner/equity buy-in OR some sort of raise/bought deal to keep us going. Going to be a volatile ride until the infused product hype in October so I am now switching to swing trades. Don't hate me.
Good post as always INVISTIGATOR. Let's not forget APHA has maiantained decent margins throughout . While ACB's margins have tanked. Let's not also forget that APHA has had the best in stock postion so far. Let's not forget that APHA has 80%+ of Shoppers Drug Mart sales